Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

422.32 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Nov 20, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

68 69 Next >

3 Biotech Stocks to Buy on the Dip: August 2024 ↗

August 15, 2024

These are three of the best biotech stocks to buy on the dip due to their strong fundamentals and market positioning.

Via InvestorPlace

Prediction: These 4 Future Technologies Will Be Millionaire-Makers -- and Here Are the Top Stocks to Buy Now to Profit From Them ↗

August 15, 2024

These technologies could be game-changers. And they could make forward-thinking investors a lot of money.

Via The Motley Fool

2 Biotech Stocks to Buy Hand Over Fist in August ↗

August 12, 2024

Both of these biotechs are highly innovative companies.

Via The Motley Fool

Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals ↗

August 09, 2024

Via Benzinga

The 3 Best Biotech Stocks to Buy in August 2024 ↗

August 08, 2024

These biotech stocks are leading the way with groundbreaking therapies and robust fundamentals offering superb upside ahead.

Via InvestorPlace

Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England

August 07, 2024

From Vertex Pharmaceuticals

Via Business Wire

Vertex Slumps On Light Second-Quarter Despite Hiked 2024 Outlook ↗

August 01, 2024

The company's sales came in a hair light with losses wider than expected.

Via Investor's Business Daily

14 Analysts Assess Vertex Pharmaceuticals: What You Need To Know ↗

July 31, 2024

Via Benzinga

Is It Too Late to Buy Vertex Pharmaceuticals Stock? ↗

August 06, 2024

Shares of the rare disease drugmaker are already up more than 40% over the past year.

Via The Motley Fool

Prediction: These Could Be the Best-Performing Growth Stocks Through 2030 ↗

August 05, 2024

Great companies are found in every type of market landscape.

Via The Motley Fool

3 Biotech Stocks on Track for 50% Returns (or More) by 2028 ↗

August 04, 2024

Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028!

Via InvestorPlace

Prediction: CRISPR Therapeutics Stock Could Be a Millionaire-Maker ↗

August 04, 2024

The biotech recently became a commercial-stage company.

Via The Motley Fool

3 Unstoppable Stocks to Buy in August ↗

August 03, 2024

It's not hard to envision how all three of these stocks can deliver exceptional growth.

Via The Motley Fool

Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings ↗

July 29, 2024

The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting.

Via Benzinga

Topics Economy

Prediction: 2 Stocks That Will Be Worth More Than Johnson & Johnson 10 Years From Now ↗

August 03, 2024

These two healthcare companies have far more upside potential than Johnson & Johnson.

Via The Motley Fool

3 Biotech Stocks That Could Have Investors Grinning Soon ↗

August 02, 2024

Biotech stocks are a high risk, high reward investment and these three biotechs offer significant upside potential.

Via InvestorPlace

Magnificent 7 Lose Over $300B As Volatility Index Surges, Traders Question Fed's Timing: What's Driving Markets Friday? ↗

August 02, 2024

Wall Street is experiencing a sharp decline on the last trading day of the week, with all indices in the red at noon in New York, as a cooler-than-expected July jobs report rattled risk sentiment and...

Via Benzinga

Topics Economy

Vertex Pharmaceuticals Lifts Annual Guidance, Positive Growth For Its Cystic Fibrosis Franchise And Pain Management Pipeline ↗

August 02, 2024

Vertex Pharmaceuticals reported Q2 revenues of $2.65B, near the $2.66B estimate, with an adjusted EPS loss of $(12.83), missing the $4.14 consensus. The analyst expects strong growth in the pain...

Via Benzinga

Should Investors Worry About Vertex Pharmaceuticals $3.6 Billion Q2 Loss? Not Even for a Second. ↗

August 02, 2024

Vertex's first loss in years is a big nothingburger.

Via The Motley Fool

Vertex Pharmaceuticals (VRTX) Q2 2024 Earnings Call Transcript ↗

August 01, 2024

VRTX earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

Vertex Reports Second Quarter 2024 Financial Results

August 01, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Got $500? 2 Compelling Growth Stocks to Buy and Hold Forever ↗

August 01, 2024

These businesses are looking like increasingly attractive buys.

Via The Motley Fool

The Top 3 Biotech Stocks to Buy Now Summer 2024 ↗

July 31, 2024

These biotech stocks are well-positioned to generate high returns for investors due to their significant growth prospects.

Via InvestorPlace

US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday? ↗

August 01, 2024

Markets experienced a sharp downturn, driven by heightened geopolitical tensions and economic uncertainties that negatively impacted investor risk sentiment, just a day after the Federal Open Market...

Via Benzinga

Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain

July 30, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November ↗

August 01, 2024

After Wednesday’s tech-led rebound amid the Federal Reserve’s rate decision, the stock market could be in for further gains. The major index futures point to a higher opening, although suggesting a...

Via Benzinga

DexCom Stock Plunged Over 40% Last Week. Are Eli Lilly's and Novo Nordisk's Drugs to Blame? ↗

July 30, 2024

DexCom faces several challenges, but GLP-1 drugs aren't big problems for the company right now.

Via The Motley Fool

The Top 3 Cathie Wood Stocks to Buy Now: Summer 2024 ↗

July 29, 2024

The investing guru likes to take the pulse of where the world will be tomorrow and these Cathie Wood stocks reflect that vision.

Via InvestorPlace

2 No-Brainer Growth Stocks to Buy With $1,000 Right Now ↗

July 28, 2024

These companies are paving the way to future growth and market share in their respective industries.

Via The Motley Fool

Is Vertex Pharmaceuticals' Monopoly in Danger? ↗

July 25, 2024

As a shareholder, I am nowhere close to panic mode.

Via The Motley Fool

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

68 69 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.